Market capitalization | $18.65m |
Enterprise Value | $-47.34m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.96 |
EV/Sales (TTM) EV/Sales | -4.95 |
P/S ratio (TTM) P/S ratio | 1.95 |
P/B ratio (TTM) P/B ratio | 0.31 |
Revenue growth (TTM) Revenue growth | 131.82% |
Revenue (TTM) Revenue | $9.57m |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
5 Analysts have issued a Spruce Biosciences Inc forecast:
5 Analysts have issued a Spruce Biosciences Inc forecast:
Jun '24 |
+/-
%
|
||
Net Profit | -9.18 -9.18 |
28%
28%
|
|
Depreciation and Amortization | 0.01 0.01 |
86%
86%
|
|
Stock Compensation | 1.69 1.69 |
39%
39%
|
|
Operating Cash Flow | -11 -11 |
658%
658%
|
|
Investments | - - |
-
|
|
Dividend Paid | - - |
-
|
|
Free Cash Flow | -11 -11 |
658%
658%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Spruce Biosciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on developing novel therapies for rare diseases affecting the endocrine system. The company was founded in 2014 and is headquartered in Daly City, CA.
Head office | United States |
CEO | Javier Szwarcberg |
Employees | 29 |
Founded | 2014 |
Website | www.sprucebio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.